317 related articles for article (PubMed ID: 20179258)
1. Pitavastatin: a new HMG-CoA reductase inhibitor.
Wensel TM; Waldrop BA; Wensel B
Ann Pharmacother; 2010 Mar; 44(3):507-14. PubMed ID: 20179258
[TBL] [Abstract][Full Text] [Related]
2. Pitavastatin calcium: clinical review of a new antihyperlipidemic medication.
Yee LL; Wright EA
Clin Ther; 2011 Aug; 33(8):1023-42. PubMed ID: 21816477
[TBL] [Abstract][Full Text] [Related]
3. Pitavastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia.
Ahmad H; Cheng-Lai A
Cardiol Rev; 2010; 18(5):264-7. PubMed ID: 20699675
[TBL] [Abstract][Full Text] [Related]
4. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin.
da Silva PM
Am J Cardiovasc Drugs; 2011; 11(2):93-107. PubMed ID: 21446776
[TBL] [Abstract][Full Text] [Related]
5. A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia.
Park S; Kang HJ; Rim SJ; Ha JW; Oh BH; Chung N; Cho SY
Clin Ther; 2005 Jul; 27(7):1074-82. PubMed ID: 16154486
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia.
Sansanayudh N; Wongwiwatthananukit S; Putwai P; Dhumma-Upakorn R
Ann Pharmacother; 2010 Mar; 44(3):415-23. PubMed ID: 20179259
[TBL] [Abstract][Full Text] [Related]
8. Pitavastatin for the treatment of primary hyperlipidemia and mixed dyslipidemia.
Gotto AM; Moon J
Expert Rev Cardiovasc Ther; 2010 Aug; 8(8):1079-90. PubMed ID: 20670185
[TBL] [Abstract][Full Text] [Related]
9. Searching the place of pitavastatin in the current treatment of patients with dyslipidemia.
Barrios V; Escobar C; Zamorano JL
Expert Rev Cardiovasc Ther; 2013 Dec; 11(12):1597-612. PubMed ID: 24215190
[TBL] [Abstract][Full Text] [Related]
10. Pitavastatin.
Mukhtar RY; Reid J; Reckless JP
Int J Clin Pract; 2005 Feb; 59(2):239-52. PubMed ID: 15854203
[TBL] [Abstract][Full Text] [Related]
11. Pitavastatin: a new 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor for the treatment of hyperlipidemia.
Baker WL; Datta R
Adv Ther; 2011 Jan; 28(1):13-27. PubMed ID: 21170619
[TBL] [Abstract][Full Text] [Related]
12. Rosuvastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia.
Cheng-Lai A
Heart Dis; 2003; 5(1):72-8. PubMed ID: 12549990
[TBL] [Abstract][Full Text] [Related]
13. Pitavastatin: an overview.
Saito Y
Atheroscler Suppl; 2011 Nov; 12(3):271-6. PubMed ID: 22152281
[TBL] [Abstract][Full Text] [Related]
14. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
15. New evidence on pitavastatin: efficacy and safety in clinical studies.
Teramoto T; Shimano H; Yokote K; Urashima M
Expert Opin Pharmacother; 2010 Apr; 11(5):817-28. PubMed ID: 20201733
[TBL] [Abstract][Full Text] [Related]
16. Rosuvastatin in the management of hyperlipidemia.
Cheng JW
Clin Ther; 2004 Sep; 26(9):1368-87. PubMed ID: 15531000
[TBL] [Abstract][Full Text] [Related]
17. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
18. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
Hilleman DE; Phillips JO; Mohiuddin SM; Ryschon KL; Pedersen CA
Clin Ther; 1999 Mar; 21(3):536-62. PubMed ID: 10321422
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison.
Saito Y; Yamada N; Teramoto T; Itakura H; Hata Y; Nakaya N; Mabuchi H; Tushima M; Sasaki J; Goto Y; Ogawa N
Arzneimittelforschung; 2002; 52(4):251-5. PubMed ID: 12040967
[TBL] [Abstract][Full Text] [Related]
20. Optimal low-density lipoprotein cholesterol lowering--morning versus evening statin administration.
Plakogiannis R; Cohen H
Ann Pharmacother; 2007 Jan; 41(1):106-10. PubMed ID: 17200427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
